| Literature DB >> 23256610 |
Marcus M Wagner1, Joel K Curé, Jimmy J Caudell, Sharon A Spencer, Lisle M Nabell, William R Carroll, James A Bonner.
Abstract
BACKGROUND: The utility of definitive radiotherapy (RT) for locoregionally advanced squamous cell carcinoma (SCC) of the larynx or hypopharynx in the setting of thyroid or cricoid cartilage invasion (TCCI) is controversial. A retrospective review of our experience was performed.Entities:
Mesh:
Year: 2012 PMID: 23256610 PMCID: PMC3551796 DOI: 10.1186/1748-717X-7-219
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Figure 1Illustration and CT images of major (left) and minor (right) thyroid or cricoid cartilage invasion (TCCI). The AJCC 7th edition staging manual for laryngeal tumors classifies minor TCCI (i.e. invasion limited to the inner cortex) as T3 and major invasion (i.e. invasion into both inner and outer cortices) as T4. Both minor and major TCCI are staged as T4 for hypopharyngeal tumors.
Patient, Tumor, and Treatment characteristics
| Total | 87 (100) | 25 (29) |
| Gender | | |
| Male | 68 (78) | 19 (76) |
| Female | 19 (22) | 6 (24) |
| Age | Median = 57 years (range 33 – 81) | Median = 58 years (range 41 – 81) |
| Ethnicity | | |
| Caucasian/Other | 49 (56) | 13 (52) |
| African-American | 38 (44) | 12 (48) |
| KPS score | | |
| 50 - 80 | 73 (84) | 21 (84) |
| 90 - 100 | 14 (16) | 4 (16) |
| Primary site with T-stage | | |
| T3 | 44 (51) | 2 (8) |
| T4a | 30 (34) | 18 (72) |
| T4b | 4 (5) | 1 (4) |
| T4 | 8 (9) | 4(16) |
| T4b | 1 (1) | 0 (0) |
| N-stage | | |
| N0 | 34 (39) | 11 (44) |
| N1 | 11 (13) | 6 (24) |
| N2 | 35 (40) | 5 (20) |
| N3 | 7 (8) | 3 (12) |
| Overall Stage | | |
| III | 24 (28) | 1 (4) |
| IVA | 53 (61) | 20 (80) |
| IVB | 10 (11) | 4 (16) |
| Concurrent Therapy | | |
| None | 9 (10) | 2 (8) |
| Cetuximab | 6 (7) | 1 (4) |
| Cytotoxic Chemotherapy | 72 (83) | 22 (88) |
| Neoadjuvant Chemotherapy | | |
| No | 75 (86) | 21 (84) |
| Yes | 12 (14) | 4 (16) |
| Fractionation of RT | | |
| Conventional | 39 (45) | 9 (36) |
| Altered Fractionation | 48 (55) | 16 (64) |
| IMRT | | |
| Yes | 52 (60) | 15 (60) |
| No | 35 (40) | 10 (40) |
| Local Recurrence | | |
| Yes | 17 (20) | 7 (28) |
| No | 70 (80) | 18 (72) |
| Regional Recurrence | | |
| Yes | 5 (6) | 1 (4) |
| Synchronous with LR | 3 (60) | 1(100) |
| Isolated | 2 (40) | 0 (0) |
| No | 82 (94) | 24 (96) |
| Distant Metastasis | | |
| Yes | 16 (18) | 4 (16) |
| No | 71 (82) | 21 (84) |
* 11 of 12 received concurrent chemoradiotherapy after induction and one received radiotherapy alone.
Local Control and Overall Survival at 2 years
| All patients | 87 | 76% | | 64% | |
| Any TCCI | 25 | 65 | 0.15 | 64 | 0.86 |
| No TCCI | 62 | 80 | | 65 | |
| Minor TCCI | 8 | 86 | 0.87 | 63 | 0.97 |
| No TCCI | 62 | 80 | | 65 | |
| Major TCCI | 17 | 55 | 0.045 | 65 | 0.82 |
| No or minor TCCI | 70 | 81 | 64 |
Figure 2Kaplan-Meier curves for local control comparing no or minor TCCI (solid) versus major TCCI (dashed). Two-year local control for patients with no or minor TCCI was 81% compared to 55% with major TCCI (p=0.045).
Organ Preservation at 2 years
| All patients | 55% | | 41% | |
| Any TCCI | 44 | 0.28 | 35 | 0.45 |
| No TCCI | 60 | | 44 | |
| Minor | 50 | 0.64 | 38 | 0.87 |
| No TCCI | 60 | | 44 | |
| Major TCCI | 41 | 0.31 | 34 | 0.38 |
| No or minor TCCI | 58 | 44 |
Figure 3Kaplan-Meier curves for overall survival comparing overall survival for no or minor TCCI (solid) versus major TCCI (dashed). Two-year overall survival for patients with no or minor TCCI was 64% and 65% for major TCCI (p=0.82).